Safety of Hyaluronic Acid and Botulinum Toxin Aesthetic Treatment Among Breast Cancer Patients
Journal of Case Reports and Reviews in Medicine · 2025
DOI: 10.64978/jcrrm-0114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Case Reports and Reviews in Medicine, 2025. Verfasst von Magda Palka-Kotlowska und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Aesthetic and functional consequences of cancer treatments often affect the quality of life and self-image of breast cancer survivors. Increasingly, patients seek nonsurgical aesthetic procedures such as hyaluronic acid (HA) fillers and botulinum toxin type A (BTX-A) treatments. However, evidence regarding the safety of these procedures in this population is limited.
Methods
We conducted a systematic literature review to evaluate the safety and efficacy of facial aesthetic treatments using HA fillers and BTX-A in breast cancer patients. Articles involving oncologic populations and aesthetic procedures were identified through major medical databases.
Results
The search revealed scarce data on facial aesthetic treatments in breast cancer survivors. Only one post-marketing study addressed aesthetic treatments in this population, reporting favorable safety outcomes in nine breast cancer patients undergoing HA filler and BTX-A treatment after completing chemotherapy. Additional literature focused on other oncological applications of BTX-A, such as pain and spasticity management, confirming its safety profile. Although HA has been used in reconstructive and supportive oncology care, few complications were noted when administered outside periods of active oncologic treatment.
Conclusion
The use of BTX-A and HA for facial aesthetic purposes appears safe in breast cancer patients who have completed chemotherapy and radiotherapy at least six months prior, provided their general health is stable. There is insufficient evidence to recommend these treatments during ongoing systemic therapies. As survivorship care increasingly prioritizes body image and quality of life, further research is warranted to establish evidence-based guidelines in onco-aesthetic medicine.
Zitieren
APA
Palka-Kotlowska, M., Custodio-Cabello, S., Pacheco-Barcia, V., Acebes, E. O., Chacón-Ovejero, B., Insua-Nipoti, E., & Cabezon-Gutierrez, L. (2025). Safety of Hyaluronic Acid and Botulinum Toxin Aesthetic Treatment Among Breast Cancer Patients. Journal of Case Reports and Reviews in Medicine. https://doi.org/10.64978/jcrrm-0114
Vancouver
Palka-Kotlowska M, Custodio-Cabello S, Pacheco-Barcia V, Acebes EO, Chacón-Ovejero B, Insua-Nipoti E, et al. Safety of Hyaluronic Acid and Botulinum Toxin Aesthetic Treatment Among Breast Cancer Patients. Journal of Case Reports and Reviews in Medicine. 2025. doi:10.64978/jcrrm-0114
BibTeX
@article{PalkaKotlowska2025,
author = {Palka-Kotlowska, Magda and Custodio-Cabello, Sara and Pacheco-Barcia, Vilma and Acebes, Eduardo Oliveros and Chacón-Ovejero, Beatriz and Insua-Nipoti, Emilce and Cabezon-Gutierrez, Luis},
title = {Safety of Hyaluronic Acid and Botulinum Toxin Aesthetic Treatment Among Breast Cancer Patients},
journal = {Journal of Case Reports and Reviews in Medicine},
year = {2025},
doi = {10.64978/jcrrm-0114}
}
EUVIMED